OQS
IOVA icon

Occudo Quantitative Strategies’s Iovance Biotherapeutics IOVA Stock Holding History

Occudo Quantitative Strategies’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-73,676
Closed -$471K – 1040
2022
Q4 		$471K Sell
73,676
-97,295
-57% -$760K 0.05% 518
2022
Q3 		$1.64M Buy
+170,971
New +$1.97M 0.13% 237
2021
Q4 		– Sell
-25,363
Closed -$625K – 1149
2021
Q3 		$625K Buy
25,363
+981
+4% +$23.1K 0.07% 455
2021
Q2 		$634K Buy
+24,382
New +$634K 0.1% 343

Other funds holding IOVA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Occudo Quantitative Strategies's IOVA Position: Q1 2023 in Review

Occudo Quantitative Strategies sold out of Iovance Biotherapeutics (IOVA) in Q1 2023, closing a stake of 73,676 shares — an estimated $471K sold.

Occudo Quantitative Strategies first reported a position in IOVA in Q2 2021 and held it in 4 quarters. The position peaked at $1.64M in Q3 2022. 228 funds tracked by Wall St. Rank hold IOVA as of Q1 2023.

  • Occudo Quantitative Strategies reported no remaining Iovance Biotherapeutics position as of Q1 2023 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 73,676 Iovance Biotherapeutics shares in Q1 2023, an estimated $471K.
  • Occudo Quantitative Strategies first reported a position in Iovance Biotherapeutics in Q2 2021 and held it in 4 quarters.
  • Occudo Quantitative Strategies's Iovance Biotherapeutics position peaked at $1.64M in Q3 2022.
  • 228 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2023.

Based on Occudo Quantitative Strategies's 13F filing for Q1 2023, filed 15 May 2023.